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Abstract 
B-cell lymphomas encompass a large number of disease entities clinically ranging from 
indolent to aggressive.  The defining pathological features usually predict clinical course, 
with small and large B-cell lymphomas correlating to low-grade versus high-grade 
features, but discordant situations may be encountered. Two sessions of the workshop 
of the XVIII meeting of the European Association for Haematopathology (EAHP) held in 
Basel in 2016 addressed this topic. One session illustrated various facets of 
“aggressiveness” in indolent lymphomas, either peculiar clinical manifestations, 
cytological variants or unusual genetic features, as well as several examples of 
progression or transformation to a more aggressive disease. Another session 
exemplified large B-cell lymphomas with unexpected indolent behavior including cases 
arising in well-defined body compartments or in sanctuary sites.  This paper describes 
the features of the cases presented in both groups, highlights the most salient points of 
discussion raised by the submitters and the panel, and summarizes current knowledge 
and recommendations relevant to diagnostic pathology practice. 
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Introduction 
Indolent lymphoma is defined as a lymphoma which tends to grow and spread slowly 
and has few symptoms usually not requiring immediate chemotherapeutic intervention 
(“low-grade”). Conversely, aggressive lymphomas are associated with a rapid growth 
and progressive clinical course (“high-grade”). These definitions, based on clinical 
presentation, clinical course and biological features, correspond to two broad categories 
of diseases and pathological entities [52]. 
Indolent lymphoma equates to small B-cell lymphoma entities, the most frequent 
and prototype being follicular lymphoma, followed by small lymphocytic 
lymphoma/chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, marginal 
zone lymphoma (of extranodal, nodal and splenic types) and hairy cell leukemia [23]. 
Mantle cell lymphoma, although composed usually of small B cells, is typically 
characterized by an aggressive behavior. Despite slow disease evolution and treatment 
with treatment resistance in some instances, and there is a cumulative risk of 
transformation to a high-grade lymphoma [52, 19]. 
Diffuse large B-cell lymphomas represent the prototype of aggressive B-cell 
lymphomas, which in principle require immediate treatment often with poly-
lymphomas that have high-grade morphological features and indolent clinical 
behaviour, which typically arise in well-defined body compartments or in sanctuary 
sites. 
This paper summarizes two sessions of the workshop of the XVIII meeting of the 
European Association for Haematopathology (EAHP) held in Basel in 2016. These 
sessions of the workshop were dedicated to B-cell lymphomas with discordance 
between pathological features and clinical behaviour. One session comprised 47 cases 
illustrating various facets of “aggressiveness” in indolent lymphomas, either peculiar 
clinical manifestations, cytologic variants or unusual genetic features, as well as several 
examples of progression or transformation to a more aggressive disease. The other 
session comprised 13 cases exemplifying large B-cell lymphomas with unexpected 
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responsiveness, indolent lymphomas essentially represent incurable chronic diseases.
They may pose clinical issues due to the tumor mass, or a more rapidly evolving disease
chemotherapy associated with an immunological agent, resulting in long-term
remission/cure in more than 50% of the patients.  However, there is a group of
4 
indolent behaviour. 
INDOLENT LYMPHOMAS WITH AGGRESSIVE FEATURES 
Follicular lymphomas 
Follicular lymphoma (FL) is one of the most common non-Hodgkin lymphomas (NHL) in 
Western countries accounting for 20-30% of adult lymphomas and 70% of indolent 
NHLs [52]. FL typically exhibits a follicular growth pattern and is composed of 
centrocytes admixed with a variable proportion of centroblasts. The cells have a CD20+ 
CD5- CD10+, BCL6+, BCL2+ immunophenotype and 80-90% carry the t(14;18)(q32;q21) 
suggestive of more aggressive behavior. 
Follicular lymphoma with double/triple hit MYC/BCL2/BCL6 
Four cases of de novo FL with double-hit (DH) BCL2/MYC (#321, P. Mroz) or triple-hit 
(TH) BCL2/BCL6/MYC (#102, G. Caponetti; #386, D. Weisenburger; #171, P. Farinha) 
rearrangements were reviewed by the panel. In contrast to these aggressive cytogenetic 
features, all of them were de novo non-transformed FL, grade 1/2 (n=3) or grade 3A 
(n=1), with classical CD20+, CD3-, CD10+, BCL6+, BCL2+ immunophenotype. MYC 
protein expression was less than 10% in 2 cases and expressed in 80% of the tumor cells 
in the other 2 cases, and the proliferative index (PI) evaluated by Ki67 immunostaining 
ranged from 10% to 80%. The MYC partner gene could be investigated in 3 of 4 cases 
and was of non-IG subtype (including the CD96 gene) in the 2 cases with <10% MYC 
protein positive tumor cells, and IGH in one case with high MYC expression. One patient 
had localized disease but three patients presented with asymptomatic stage IV disease, 
including one patient with exclusively skeletal disease and multiple bone lesions who 
remained untreated for 1 year before being lost to follow-up (#102). Interestingly, one 
patient with TH FL relapsed at 9 years with a FL 1/2 carrying an isolated BCL2 break 
and experienced complete remission without therapy (#171). None of the three patients 
with available follow-up had an aggressive clinical course. 
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IGH-BCL2 translocation. Progression of FL usually refers to transition from grade ½ to
3A or evolution to a more diffuse growth pattern, while transformation is defined by a
diffuse high-grade B-cell lymphoma. In addition, FL may display a variety of features
5 
MYC translocation in de novo non-transformed FL 1-2/3A is a rare event. Six cases 
of FL with MYC rearrangement and germline BCL2 gene have been described with a 
follicular and diffuse architecture, grade 1 to 3 morphology and an indolent behaviour 
[34]. Less than 20 well documented cases of FL 1/2 with double-Hit MYC/BCL2 have 
been published including a recent series of 7 patients (median age 47 years with a male 
predominance) with stage IV nodal and extranodal disease [37]. The DH FL were grade 
1-2 to 3A with a follicular growth pattern, without any blastoid morphological features, 
classical immunophenotype, MYC protein expression <30% and Ki67 ranging from 5-
50%. Three patients treated with standard regimen for FL had a poor outcome and 4 
patients treated with a more intensive regimen for DH lymphoma achieved complete 
remission. In total, DH/TH de novo FL patients’ prognosis remains unpredictable with 
either unexpectedly good outcome as in the cases submitted to the workshop, or more 
FL with high proliferative index 
Two cases of FL with high Ki67 PI were submitted: one extranodal BCL2-negative (with 
clones 124 and E17 antibodies) FL 1/2 without detectable BCL2 and BCL6 breaks with 
bilateral breast involvement in a 82 year-old man (#256, W. Xue) and one disseminated 
FL 1/2 with a classical immunophenotype, t(14;18) positive in a 66 year-old man (#318, 
N. Panesar). The latter case displayed follicles with a starry-sky appearance, a 
proliferative index of 100% and was extensively documented by array-CGH analysis 
showing gains of 7q31, losses at 1p36 and 9p24 (CDKN2A, CDKN2B). The patient 
responded well to 6 cycles of R-bendamustine followed by rituximab maintenance 
therapy. 
Ki67 index correlates in general with the FL grade but a high Ki67 level (30 to 
40% or more) is observed in up to 20 percent of FL 1/2. As recommended in the report 
of the Istanbul EAHP meeting, the WHO grading should be retained for such cases with 
an additional comment that FL 1/2 with high PI might pursue a more aggressive course 
[59]. Delineation of these forms from FL with blastoid features is also important. 
Currently the prognostic significance remains controversial.  Blastoid features refer to 
cytological features reminiscent of precursor cells, i.e. medium-sized cells with finely 
distributed chromatin and occasional presence of small nucleoli, resembling 
lymphoblasts or small centroblasts. As emphasized in the past [61], there is poor 
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aggressive behavior as recently reported [37].
6 
reproducibility in recognition of this variant, and accordingly several cases submitted to 
the workshop where either not recognized as blastoid by the submitter and designated 
as such by the panel, or vice-versa. When blastoid features are encountered, the first step 
is to rule out transformation to a high-grade lymphoma, or lymphoblastic lymphoma (by 
performing TdT staining); in the context of follicular lymphoma, the term “follicular 
lymphoma not gradable with blastoid features” is recommended [61]. 
FL with BCL2 or NOTCH gene mutations 
FL may be associated with different mutational profiles with variable prognostic 
significance. Three cases were submitted with acquired BCL2 or NOTCH mutations, or 
with inherited TP53 mutation in the context of Li Fraumeni syndrome for one case. One 
case of BCL2-mutated FL grade 1/2 (#112, RL. King) occurred in a 42-year-old male, 
who presented with pancytopenia, extensive lymphadenopathy and died after 6 years 
following 6 different lines of therapy including autologous cell transplant. BCL2 coding 
sequence mutations are reported to occur in 12% of FL 1/2 at diagnosis using Sanger 
sequencing. Mutations in the region of BCL2 coding for the epitope recognized by the 
common anti-BCL2 antibody may cause false negative immunohistochemistry results, 
and alternative antibodies recognizing other epitopes may be necessary to demonstrate 
BCL2 expression in these cases [1, 51]. FL with BCL2 mutations have been associated 
with increased risk of transformation and shortened survival in a retrospective series of 
de novo FL treated in the pre-rituximab era [11]. However, more sensitive deep DNA 
sequencing methods have shown up to 76% BCL2 mutation rates in FL [42] and further 
studies are warranted to confirm the prognostic value of BCL2 mutations in FL patients 
treated with rituximab-containing chemotherapy.  
One case highlighted the peculiar features of NOTCH-mutated FL (#266, F. Sen). In 
this 43 year-old woman a cervical lymph node biopsy was first performed showing a 
NOTCH1-mutated B-cell lymphoma with a marginal zone pattern and increased large 
cells. Splenectomy performed a few months later displayed a CD10-, BCL2-, t(14;18) 
negative FL 1/2 with a high proliferative index (Figure 1). Although the relationship 
between the 2 diseases was difficult to assess on morphological grounds, additional 
studies performed by the panel showed that they were clonally related. NOTCH 
mutations occur in about 6% of FLs, are associated with a female predominance, lower 
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7 
frequency of t(14;18), higher incidence of spleen involvement, and a significant 
association with DLBCL [31]. NOTCH mutations do not seem to have a prognostic impact 
in FL but additional studies on larger series are needed.  
Transformed FL 
Eleven cases of transformed FL (tFL) were submitted to the workshop. FL 
transformation into more aggressive lymphoma is observed in 2% to 3% of patients per 
year [33, 61]. FL transforms into different histologic subtypes, including DLBCL, B-cell 
lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt 
lymphoma (formerly BCLu) or with blastoid morphology (TdT-negative) and 
lymphoblastic type (TdT-positive) lymphoma. According to the WHO 2016 update, the 
former BCLu cases are now distributed into 2 new categories: high-grade B-cell 
lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations (for those carrying 
double-hit=DH or triple Hit=TH) and HGBL-not otherwise specified (NOS) for the others 
[54]. The morphologic subtype (DLBCL vs BCLu vs blastoid vs lymphoblastic) and the 
statement “transformed from FL” should be added in the pathology report (example: 
HGBL, with BCL2 and MYC rearrangement, DLBCL morphology, transformed from FL”). 
It is recommended to demonstrate the clonal relationship between the 2 components. 
Importantly, HGBL-DH should be restricted to mature aggressive lymphomas and 
therefore excludes FL and lymphoblastic lymphomas with DH/TH. The 11 tFL submitted 
to the workshop included 2 DLBCL associated with FL and 9 HGBL-DH/TH with DLBCL 
(n= 7), BCLu (n=1) or blastoid morphology (n=1) (#263, R. Felgar)(Figure 2). In most 
HGBL, FL and HGBL components were diagnosed simultaneously at different sites, with 
FL in nodal or extranodal (lung, spleen, salivary gland) locations and HGBL in the bone 
marrow (BM) being the most frequent scenario, highlighting the importance of staging 
bone marrow biopsy. Only two cases had HGBL nodal involvement with concurrent FL in 
the bone marrow. One case with FL 1/2 in the spleen had BM and leukemic 
dissemination of the HGBL (#280, SS. Chuang). 
Interestingly, in 2 cases the tFL was EBV-associated.  Acquisition of EBV during 
transformation is overall a rare event and might be confused with the probably more 
frequent reactivation of intra- and peritumoral EBV in non-neoplastic cells. Case 105 (M. 
Tinguely) was a 50 year-old male who presented initially with nodal EBV+ DLBCL NOS
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8 
with BCL2/BCL6 rearrangements and who achieved complete remission following R-
CHOP therapy. He relapsed 2 years later with EBV-negative clonally related FL 1/2 
carrying BCL2/BCL6 breaks. Case 355 (D. De Jong) was a 74 year-old male with nodal 
EBV+ HGBL-DH MYC/BCL2 with DLBCL morphology and FL 1/2 in the BM. Latency III 
EBV infection was demonstrated in tumor cells (LMP+, EBNA2+, EBERs+) questioning 
whether this case should be included in the HGBL or EBV+ DLBCL NOS category, and the 
potential role of EBV in HGBL transformation in these two cases. 
Regarding the molecular subtypes of tFL, 9 were germinal center-like (GC) and the
2 EBV-associated tFL were non-germinal center-like (NGC) according to Hans algorithm
[26]. This is consistent with the literature where tFL have been reported as germinal
center (GC), activated B-cell type (ABC) or unclassified in 80%, 16% and 4% 
respectively using transcriptomic analysis [33]. Four out of 6 patients with clinical 
follow-up died, one had progressive disease and one achieved complete remission (case 
295, 7 months follow-up). 
Lymphoplasmacytic lymphoma 
Lymphoplasmacytic lymphoma (LPL) is a neoplasm of small lymphocytes, plasmacytoid, 
lymphocytes and plasma cells, usually involving the bone marrow and sometimes lymph 
nodes and spleen, which does not fulfill the criteria for other small B-cell lymphomas 
that may have plasmacytic differentiation (Figure 3A and 3C) [53]. The majority of LPL 
patients have Waldenström’s macroglobulinemia, (WM) (defined as bone marrow 
involvement by LPL and a IgM serum paraprotein of any concentration) but this feature 
is not mandatory for LPL diagnosis [53]. More than 90% of LPL have MYD88 L265P 
mutation, but this abnormality is not specific as it is also encountered in other small B-
cell lymphomas and a subset of DLBCLs [55]. About 30% of the patients harbor somatic 
mutations in CXCR4 (most commonly the nonsense truncating S338X, or frameshift 
mutations in the C-terminal domain) in addition to the activating MYD88 L265P 
mutation, and this genotype tends to correlate with higher disease activity [50]. The 
uncommon cases with wild-type MYD88 and those with CXCR4 mutations have reduced 
responsiveness to Bruton’s tyrosine kinase inhibitor ibrutinib [57, 58, 50]. 
The Bing-Neel syndrome designates a very rare manifestation of WM with 
neurological symptoms, due to infiltration of the central nervous system by 
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9 
lymphoplasmocytoid cells, or due to humoral factors in the absence of cellular infiltrate 
of the brain or cerebrospinal fluid [38, 17]. Case #202 submitted by L. Venkatraman
illustrated an example of this complication in a patient who presented with depression, 
headache and visual symptoms four years after a diagnosis LPL/WM. Imaging 
abnormalities were detected by MRI but no abnormal cellular infiltrate was definitively 
demontrated. Bing-Neel syndrome by definition excludes cases of transformation to 
high-grade lymphoma, but this patient later developed transformation to DLBCL 
involving the lacrimal gland and the brain. 
Transformation of LPL to DLBCL occurs rarely (cumulative incidence <5% at 15 
years) and is associated with a bad outcome [9, 35]. Development of Hodgkin lymphoma 
has been reported rarely in LPL patients [46]. Five cases of transformed LPL were 
submitted to the workshop (#171, M. Buehler; #238, L. Venkatraman; #202, C. 
Dommann-Scherrer; #332, T.N. Aladily; #252, H. Van Krieken). The patients had a 5 to 
15 years history of LPL and four had WM. Among 4 cases tested for mutations, all were 
positive for MYD88 L265P, 3 were wild-type for CXCR4 and 1 had a CXCR4 frameshift 
mutation. Transformation was observed in lymph nodes in three patients and in 
extranodal sites in two. Histology at transformation was DLBCL in 4 cases including a 
case of plasmablastic lymphoma (figure 3A-B), and there was an exceptional case of 
clonally related EBV-positive lymphoproliferation with Hodgkin-like features in one 
patient who had undergone stem cell transplantation for disseminated LPL (#252) 
(Figure 3C-F). MYC rearrangement was documented in 2 DLBCL cases at transformation. 
Three of the patients with transformation to DLBCL died of disease, sometimes after 
prolonged evolution, but one patient is alive with disease persistent in the form of low-
grade LPL one year after transformation and chemotherapy. 
LPL may include an increased proportion of large cells, and there are no precise 
guidelines as to the threshold to consider transformation to DLBCL. Two cases were 
submitted (#317, D. Gur and #364, E. Mason), that were considered by the panel to 
represent LPL enriched in large cells. Both patients had massive bone marrow 
involvement, comprising an admixture of small and larger blastic cells. The latter, 
however, did not form confluent sheets and based on this, it was felt that the diagnosis 
of DLBCL was not warranted. One of those patients had a long history of LPL with 
multiple lines of therapy, and MYD88 mutated/CXCR4 wild-type genotype together with 
an ARID1 mutation (Figure 3G-H). A biopsy in a second patient was obtained three 
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10 
months after initial diagnosis and after worsening of anemia, a peculiar feature in this 
case was the demonstration of an as yet unreported genotype (MYD88 wild-type/CXCR4 
frameshift mutation). 
B-cell leukemias 
Small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL) is an 
indolent neoplasm of small mature CD5+ CD23+ B-cells, with a small proportion of
prolymphocytes distributed within proliferation centres seen in tissue sections [53]. 
Clinical progression has been associated with histologically aggressive forms, 
characterized by expanded proliferation centers or increased proliferation fraction 
(Ki67>40%) [15, 20] or an increased proportion of prolymphocytes (>10%) in the 
peripheral blood [40]. 
Transformation of CLL into an aggressive disease may result from 
prolymphocytoid transformation (defined by more than 55% prolymphocytes in the 
peripheral blood) or Richter’s syndrome [53]. The two cases of prolymphocytoid 
transformation of CLL [59, D. Grier and #170, B. Rea and A. Bagg] occurred at 10 and 13 
years after CLL diagnosis and exhibited both typical peripheral blood morphology. In 
case #170 (Figure 4A) the karyotype obtained at transformation contained a 
t(8;14)(q24;q32) translocation, but neither MYC nor IGH were involved in the 
rearrangement, which was retrospectively found to be already present at CLL diagnosis. 
Interestingly a number of candidate oncogenes map to these loci (ZHXQ @ 8q24 and 
TCL1 @ 14q32) and are possibly deregulated by the rearrangement. 
Richter’s syndrome (RS) is a term used to designate a clinical situation 
characterized by the sudden transformation into an aggressive disease in a patient with 
CLL/SLL, which occurs in 5- 10% of the cases [8, 3, 28]. Histologically, most cases are 
represented by DLBCLs but there is also a Hodgkin variant of RS accounting for a 
minority of the cases [41]. Although RS and “Richter transformation” seem to be used 
interchangeably in the literature, and most RS represent clonal evolution of the 
preexisting SLL/CLL, there is a subset of the cases that are clonally unrelated to the CLL 
and represent secondary malignancies. The latter includes a small proportion of DLBCLs 
and the majority of Hodgkin-type cases [12, 36]. Interestingly the two RS subsets 
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defined by clonal relationship are associated to distinct molecular features with a higher 
proportion of TP53 alterations found in clonally related cases. There are different 
prognoses with clonally unrelated RS being associated to a significantly longer survival 
compared to clonally related RS who do very poorly [47]. Given the clinical impact of 
clonal relationship of the RS to the CLL, the panel recommended investigation of this 
feature in every case when possible and to restrict the use of the term “transformation” 
to cases that represent clonally-related lesions only. The definitive answer ultimately 
relies on molecular tests to compare the sequence of VDJ gene rearrangements or the 
genomic profiles of both lymphoproliferations. 
One of the cases of RS (#273, M. Sharifian) was a classical example of a 
transformation to a DLBCL clonally related to the preexisting CLL, and associated to 
acquisition of MYC rearrangement, that occurred only two years after CLL diagnosis. The 
RS presented by D. Weisenburger (#384) occurred in a patient with SLL and no 
significant lymphocytosis, and consisted of EBV-negative MYC-rearranged plasmablastic 
lymphoma clonally unrelated to the preexisting SLL. There was a complex case of a 
composite lymphoma presented by A. Perry (#348) (Figure 4B-D): the initial lymph 
node in that patient comprised FL associated with an interfollicular involvement by SLL, 
plus foci of cyclinD1-positive in situ mantle cell neoplasia, harboring a CCND1 
rearrangement confirmed by FISH. Interestingly, although both the FL and SLL had 
distinct immunophenotypes, a PCR analysis for IGH gene rearrangement demonstrated 
only a single band, and both components harbored a BCL2-IGH fusion. The patient’s 
disease later evolved towards a lymphoma with the features of classical Hodgkin 
lymphoma, EBV-negative, and the panel was able to demonstrate the presence of BCL2-
IGH fusion in the Reed-Sternberg cells. That represents an exceptional example of 
clonally related Hodgkin lymphoma complicating a composite lymphoma including 
t(14;18)-positive SLL. 
B-cell prolymphocytic leukemia (B-PLL) is a neoplasm of B prolymphocytes 
affecting the peripheral blood, bone marrow and spleen, with prolymphocytes exceeding 
55% of lymphoid cells in the peripheral blood [53]. Cases of CLL with increased 
prolymphocytes or prolymphocytoid transformation, as well as lymphoproliferations 
associated to a t(11;14) translocation fusing IGH and CCND1 are by definition excluded 
[49]. Numerical or structural abnormalities of the MYC gene have been reported in B-
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PLL [18], and were indeed present in the 3 cases submitted to the workshop. One case 
(#305, E. Hsi) (Figure 4E-G) with a complex karyotype including a t(8;14)(q24.1;q32) 
was characterized by a relatively low absolute lymphocytosis and a long indolent clinical 
course, prior to transformation to a clonally related plasmablastic lymphoma. Case 
(#302, X. Wu) with an extra MYC copy showed a typical prolymphocytic morphology in 
the blood and bone marrow (Figure 4H), had spleen involvement and a dismal 
prognosis. 
An exceptional case of hairy cell leukemia presented by M. Piris (169) 
showed massive splenic involvement by large blastic cells, while scattered smaller cells 
with a morphology of hairy cells were observed in the peripheral blood [30].  A BRAF 
mutation was demonstrated together with triple-hit involving BCL2, BCL6 and MYC 
rearrangements.  This situation generated discussions regarding the most appropriate 
classification of this case, as a high-grade B-cell lymphoma with triple hit, versus blastoid 
hairy cell leukemia. The latter designation was favored given that the peculiar clinical 
and pathological features of hairy cell leukemia were clearly present; that patient 
expired shortly after diagnosis. 
Mantle cell lymphoma 
Mantle cell lymphoma (MCL) is usually characterized by an aggressive behavior; 
however, subsets of MCL with an indolent behavior recognized over the past years, 
namely in situ mantle cell neoplasia and non-nodal, leukemic MCL are now 
individualized in the revised WHO classification [29, 48, 54]. Leukemic non-nodal MCL is 
usually positive for cyclin D1, carries the t(11;14) translocation, but tends to be negative 
for SOX11 [29, 54]. Despite a usually indolent clinical course, these cases may transform 
and one example was illustrated by case #133 (L. Soma and S. Chen) (Figure 5). The 
patient presented with a leukemic picture comprising two components, one of small 
CD5-positive cells, the other of larger blasts with cells carrying a MYC rearrangement. 
Two other cases were presented that illustrated situations where leukemic MCL could 
be confused with CLL. In one case there was absence of cyclin D1 expression despite 
IGH-CCND1 rearrangement, in the other one due to absence of demonstrable CCND1 
rearrangement, that turned out to be cryptic on standard karyotype and not identified 
by FISH; in the latter case the clinical evolution was aggressive and the patient died of 
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disease at 8 months (142, J.Cook). 
Case #352 (E. Sabattini) exemplified a peculiar nodal MCL with mixed small 
cells and pleomorphic components, the latter showing a marginal zone pattern with 
IRTA-1 expression, SOX11 positivity and no detectable cyclin D1 expression despite the 
presence of a CCND1 gene rearrangement evidenced by FISH. Similar cases of cyclin D1-
protein-negative, t(11;14)-positive MCL have been previously reported and so far that 
phenomenon remains unexplained [48].  
 AGGRESSIVE LYMPHOMAS WITH INDOLENT CLINICAL BEHAVIOUR 
Large B-cell lymphoma associated with thrombus, myxoma, or prosthesis in the 
heart  
Primary cardiac lymphoma (PCL) is a rare disorder accounting for 1% of cardiac 
tumours and only 0.5% of extranodal lymphomas [22].  There have been reports of 
lymphomas that arise within the cardiac chambers with a particularly indolent course 
[25, 4]. Similar cases have been reported in association with cardiac prostheses, vascular 
grafts and around joint prostheses [10, 16].  In the heart the right side is involved more 
frequently than the left [25] and the lymphomas are often associated with atrial myxoma 
or prosthetic valves[4, 16]. PCL involving native heart valves is very uncommon [4, 7]. 
Two cases in the workshop illustrated the unique features of PCL (#117, A. Joshi; 
#337, A. Ruano). One case arose within a cardiac thrombus (#337) (figure 6), while the 
other was associated with thrombus attached to a bioprosthetic mitral valve [18]. The 
clinical presentation in both cases was rather non-specific including shortness of breath 
and pulmonary edema. This presentation is quite typical of PCL where the presentation 
is characteristically associated with effusions, constitutional symptoms and/or 
shortness of breath. 
Morphologically, the cells in PCL are reported to be large and embedded in fibrin 
or thrombus without invasion of the myocardium. The cells have a typical B-cell 
immunophenotype and are generally non-germinal centre type.  They are usually 
positive for EBV with a type III latency pattern [4, 7]. Both submitted cases showed 
clonal IGH gene rearrangement. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
These two cases illustrate the indolent clinical course with one patient alive and 
disease free without any further treatment. The cases in the literature also show a 
favourable outcome and recognition of these PCLs is important to avoid potential 
overtreatment. 
The pathogenesis of these lymphomas and the explanation for their unusually 
indolent behaviour remains unclear.  Most cases arise in immunocompetent patients but 
it has been suggested that there may be localised reduction of immune surveillance 
confined to the location in which the lymphoma develops [4, 43].  This may be due to 
increased local concentrations of IL-6 as a result of local inflammatory response, 
increased concentration of IL-10 locally or by the sequestration of the neoplastic cells 
within clot that is not well penetrated by normal immune regulatory cells [4]. PCLs are 
more often encountered in older aged patients and age-related immune senescence 
should also be considered as a potential contributory factor [4].  These are very rare 
lymphomas but from the cases presented in the literature it can be postulated that 
complete resection of the thrombus and/or prosthesis may be curative avoiding the 
requirement for more aggressive poly-chemotherapy.   
Effusion lymphoma associated with fluid overload 
Primary effusion lymphoma (PEL) is a rare B-cell lymphoma that is confined to body 
cavities associated with pleural, pericardial serous effusions or with peritoneal ascites. 
Typically PEL is a human herpes virus 8 (HHV8)-related lymphoma encountered in the 
context of human immunodeficiency virus (HIV) infection that has a very poor outlook 
with median survival of 3-4 months. It is characterized by a proliferation of large cells 
morphologically intermediate between immunoblastic and anaplastic large cells.  The 
cells tend to lack pan-B-cell antigens such as CD19, CD20 and CD79a while retaining 
expression of CD45 with positive staining for plasma cell and activation markers (CD38, 
CD138 and CD30). They show positive nuclear staining for HHV8-associated latent 
protein LANA and are negative for EBV. 
Cavity-based B-cell lymphomas unrelated to HHV8 infection (HHV8-unrelated 
PEL-like lymphomas) may occur in other clinical scenarios [27, 60]. These may be 
divided into effusion-based Burkitt lymphoma (with MYC rearrangement, EBV-positive 
or negative) and effusion-based large B-cell lymphomas characterized by large cell 
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morphology, absence of MYC rearrangement but possibility of MYC amplification and 
variable EBV status.  In contrast to classical PEL, the cells retain expression of pan-B cell 
markers while markers of plasma cell differentiation and activation are usually negative. 
The patients are usually older and the outlook is significantly superior to classical PEL 
with a median survival up to 10 months, while a 35% 1-year survival has been reported. 
HHV8-unrelated PEL-like lymphoma was illustrated by one case (#313, M.F. van 
den Hout). The patient was an elderly (85yrs) male with massive pericardial effusion 
but without significant previous medical history and tested negative for HIV.  The 
pericardial effusion was drained and microscopic examination revealed a population of 
large cells, many with immunoblastic morphology.  The cells stained for CD20 and 
CD79a while they were negative for CD138, CD30, HHV8 and EBER. Due to the advanced 
age of the patient and the lack of other symptoms or evidence of disseminated disease 
no further intervention was undertaken and the patient was alive and apparently 
disease free 3 months later. 
This case highlighted many of the features that distinguish classical PEL from 
PEL-like lymphoma.  PEL-like lymphoma typically presents at an older age and is usually 
associated with disorders that are associated with serous effusions such as heart failure 
or cirrhosis [5, 60].  The aetio-pathogenesis of the lymphoma is unclear but is unrelated 
to HIV or HHV8 [5, 60].  There has been a reported association with hepatitis C virus [27, 
45] and a proportion may be related to EBV [60, 56]. Due to the rarity of these
lymphomas the optimal therapy is unclear.  Many patients may be unsuitable for 
aggressive therapy but where appropriate poly-chemotherapy may be used in 
combination with anti-CD20 immunotherapy [45, 60].  It has been suggested that many 
cases may be undiagnosed as the effusion may be dismissed as being related to heart-
failure and there are cases, such as the one submitted to the workshop, that have 
received no active therapy and have regressed following fluid drainage with or without 
pleurodesis [45]. A useful diagnostic test may be fluid to serum LDH ratio which has 
been reported to be very high in these cases  [45]. 
Large B-cell lymphoma confined to peripheral nerve 
Neurolymphomatosis (NL) designates the presence of infiltration of nerve trunks, nerve 
roots, plexi and cranial nerves by lymphoma cells [24]. NL is rare and may occur as part 
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of disseminated lymphoma but less commonly the lymphomatous infiltrate is confined 
to a peripheral nerve (primary lymphoma of peripheral nerve, PLPN) [13] with a high 
proportion of the cases described in the literature involving the sciatic nerve [2]. Almost 
all of the cases of PLPN have been DLBCL [21]. The age of presentation is usually 34-72 
years (mean 57.3 years) with a higher incidence in men [21]. Deletion of the 
CDKN2A/p16 gene has been described in some cases and may be a negative prognostic 
factor [39, 14]. A pre-existing history of auto-immune disease has been suggested as a
predisposing factor [39, 14]. Possible explanations for location in peripheral nerve may 
include the presence of B cells within the peripheral nerve [44] or the expression of 
specific adhesion molecules [6]. 
A single case of PLPN was submitted to the workshop (#350, S. Dojcinov). The 
patient presented with pain in the left upper forearm and hand consistent with carpal 
tunnel syndrome. Decompression was performed but the symptoms progressed with 
flail arm and muscle wasting. Subsequent imaging studies revealed thickening of the 
brachial plexus with increased PET activity confined to the brachial plexus and median 
nerve. A nerve biopsy revealed DLBCL with expression of CD20, BCL6, BCL2 and MUM1 
while the cells were negative for CD10, CD5, CD23, CD43 and EBER. 
The case illustrated many of the typical features seen in PLPN. Reaching the 
correct diagnosis is often difficult and usually requires nerve biopsy or large resection. 
In some cases the lesion may be mass-forming and misdiagnosed as schwannoma [32].  
Most cases are treated as usual DLBCLs [24, 2, 14].  The case submitted to the workshop 
was treated with six cycles of R-CHOP chemotherapy with intra-thecal prophylaxis to 
complete response but relapsed 24 months later with contralateral brachial plexus 
involvement that was treated with intensified chemotherapy and autologous stem cell 
transplant resulting in remission that has extended so far for a further 12 months. This 
clinical behaviour is in contrast to many of the cases reported in the literature where the 
clinical outlook for NL is generally poor with median survival of around 10 months [24].  
There are frequent relapses in the central nervous system. However there is possibly a 
better prognosis for primary compared to secondary NL [24]. 
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Conclusions 
Some cases of indolent lymphomas encompass a spectrum of morphological,
immunophenotypical and genetic/molecular features that might suggest a potentially 
more aggressive behavior. All features must be interpreted in the light of the 
morphology and clinical context. In particular MYC rearrangement may be observed in 
de novo low-grade B-cell lymphomas, in the absence of histological transformation; such 
a finding should be mentioned in the diagnostic report but is not necessarily indicative 
of an increased risk of clinical progression. 
Transformation of indolent to aggressive B-cell lymphomas comprises a 
cytological spectrum including large cell, blastoid, Burkitt-like, prolymphocytoid or even 
Hodgkin-like proliferations. In follicular lymphomas, DLBCL not otherwise specified and
high-grade B-cell lymphoma double-hit represent the most common forms of 
transformation. The basis for considering histological transformation is the 
identification of sheets of large transformed cells. There remains a category of 
“intermediate” cases with an increased number of large cells not considered sufficient to 
warrant a diagnosis of transformation that are difficult to interpret. Although the high-
grade transformation is usually clonally related to the preexisting small B-cell 
lymphoma, a subset of the cases represent clonally unrelated events, a distinction that is 
important to assess given the distinct clinical behavior and prognosis in clonally related 
versus unrelated cases, especially in the context of Richter’s syndrome. 
Among large B-cell lymphomas, those that develop as localized disease in 
association with thrombi, myxoma or prosthesis in the heart appear to run an indolent 
clinical course with the option for localized treatment (e.g. resection of thrombus and/or 
prosthesis); among lymphomatous proliferations associated with effusions, those with 
“PEL-like” features associated with fluid overload and unrelated to HHV8 infection may 
regress following fluid drainage and should be distinguished from the aggressive type of 
PEL lymphoma. 
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FIGURES LEGENDS 
Figure 1 
NOTCH mutated follicular lymphoma of the spleen (case 266, courtesy from Dr F. Sen). 
H&E stains showing involvement of the white pulp of the spleen by a nodular lymphoid 
proliferation (A) composed of small atypical lymphoid cells (B). By 
immunohistochemistry, the lymphoid cells are positive for CD20 (C) negative for 
BCL2/clone 124 (D) and show a high Ki67 high proliferative index (E). 
Figure 2 
 Transformed follicular lymphoma of the lymph node to high-grade B-cell lymphoma, 
triple-hit BCL2 BCL6 and MYC, with blastoid morphology in the bone marrow (case 263, 
courtesy from Dr R. Felgar). 
H&E stain showing involvement of an axillary lymph node by a grade ½ follicular 
lymphoma (A and B) with BCL2 and BCL6 genes rearrangements (not shown), bone 
marrow aspirate showing replacement of normal elements by a blastoid population (C) 
and MYC immunohistochemistry on the bone marrow trephine biopsy showing diffuse 
and strong positivity (D). 
Figure 3 
Lymphoplasmacytic lymphoma. 
(A-B) Case 171, courtesy of Dr. Bühler.  Heavy bone marrow involvement by LPL 
composed of small lymphoid cells, lymphoplasmayctoid cells and plasma cells (A);  and 
axillary lymph node biopsy with transformation to plasmablastic lymphoma, composed 
of large cells with immunoblastic morphology, abundant cytoplasm and a CD20- CD138+ 
immunophenotype showing the same light chain restriction as the LPL and a MYC 
rearrangement. 
(C-F) Case 252 submitted by Dr. H. Van Krieken. The patient presented with nodal 
involvement by lymphoplasmacytic lymphoma containing cells with intranuclear 
inclusions (Dütcher bodies and arrows) (C); two years after autologous stem cell 
transplantation he developed a lymphoproliferation containing many atypical large cells 
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with Reed-Sternberg-like (HR-like) features and a CD30+ CD15+ EBV+ phenotype in a 
histiocytic background (D); immunostainings for Ig light chains demonstrated 
monotypic kappa restriction in the LPL (E) and the HRS-like cells (F) suggesting clonal 
relatedness between the two processes, which was further demonstrated by identical 
IGH gene rearrangement and the presence of MYD88 L285P variant in both biopsies. 
(G-H) Case 317, submitted by Dr D. Gur. Bone marrow biopsy showing massive 
infiltrate by LPL comprising an increased proportion of large cells (G) with a Ki67 
proliferation index averaging 50%. 
Figure 4 
Small lymphocytic lymphoma/Chronic lymphocytic leukemia (SLL/CLL) and B-cell 
prolymphocytic leukemia (B-PLL) (A). Prolymphoid transformation of CLL (case 170, 
courtesy of Drs B. Rea and A. Bagg): peripheral blood smears showing a majority of 
prolymphocytes characterized by prominent nucleoli.  
(B-D) Hodgkin variant of Richter’s syndrome (case 348, courtesy of Dr A. Perry). 
Lymph node involvement by a composite follicular lymphoma (upper left and lower 
right) and small lymphocytic lymphoma (interfollicular involvement) (B), later 
transformed to a lymphoproliferation with features of classical Hodgkin lymphoma (C). 
FISH analysis using a dual fusion probe IgH/BCL2 demonstrated multiple fusion signals 
in the Reed-Sternberg cells, indicating clonal relationships to the preexisting small B-cell 
lymphoproliferation (D).  
(E-G) B-cell prolymphocytic leukemia (case 305, courtesy of Dr E.D. Hsi).  Bone marrow 
histology in a case of B-PLL showing an infiltrate of small to medium-sized lymphoid 
cells with prominent nucleoli (E) and strong MYC expression (F), peripheral blood 
smear showing lymphoid cells with prominent nucleoli (G).  
(H) Bone marrow aspirate in a case of B-PLL with a massive splenomegaly, mild 
lymphocytosis and bone marrow involvement (case 302, courtesy of Dr X. Wu).  
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Figure 5 
Leukemic mantle cell lymphoma transformed to blastoid variant with MYC and CCND1 
rearrangement (case 133, courtesy of Drs  L. Soma and X. Chen). 
Peripheral blood smear showing a dual population of small lymphoid cells and larger 
cells with blastoid morphology (upper and lower panels) (A).; bone marrow aspirate 
showing massive involvement by lymphoid cells with blastoid features (B); bone 
marrow histology showing diffuse replacement of the marrow spaces by monotonous 
population of medium-sized cells with blastoid features, displaying a starry-sky pattern 
(C); chromosome analysis showing a 46, XY, del (3) (q25, q26.2), t(8;14) (q24; q32), 
t(11; 14) (q13; q32) [5]/46, XY [15]; (E-H) Bone marrow immunohistochemistry: 
lymphoid cells are positive for CD10 (E), cyclin D1 (F), MYC (G) and p53 (H). 
Figure 6 
Cardiac thrombus associated large B-cell lymphoma (Case 337, courtesy of Dr. A. 
Ruano). Large lymphoid cells are embedded in a cardiac thrombus without invasion of 
the myocardium (A). Tumor cells show expression of CD20 (B), are positive in the EBER 
in situ hybridization (C) and show a high proliferative rate in the Ki67 stain (D). 
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